C. Constance

发表

Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries.

B. Strauss, M. Tan, A. Langer, 2005, American heart journal.

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

B. Egan, K. Andersen, M. Weinberger, 2008, Journal of hypertension.

Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes.

A. Yan, M. Tan, D. Fitchett, 2006, The Canadian journal of cardiology.

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years

N. Wenger, O. Ben‐Yehuda, C. Jones-Burton, 2011, Journal of geriatric cardiology : JGC.

Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.

T. S. Chee, D. S. Kim, S. H. Lee, 2021, European journal of preventive cardiology.

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

The COVID-19 Pandemic and Coronary Angiography for ST-Elevation Myocardial Infarction, Use of Mechanical Support, and Mechanical Complications in Canada: A Canadian Association of Interventional Cardiology National Survey

D. Wood, J. Brophy, N. Dendukuri, 2021, CJC Open.

Prognostic implications of prominent R wave in electrocardiographic leads V1 or V2 in patients with acute coronary syndrome.

F. Van de Werf, A. Yan, S. Goodman, 2014, The American journal of cardiology.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, The Lancet.

Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension

K. Andersen, M. Weinberger, M. Prescott, 2009, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Renin-Angiotensin-Aldosterone System

K. Andersen, M. Weinberger, M. Prescott, 2009 .

W16-P-033 Direct statin comparison of LDL-Cvalues: An evaluation of rosuvastatin therapy (discovery — Canada)

C. Constance, M. Gupta, 2005 .

Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT‐CVD) study

M. Tan, S. Goodman, R. Welsh, 2021, International journal of clinical practice.

Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies

Anil Gupta, M. Abeel, C. Constance, 2021, Advances in Therapy.

The good and the bad: what researchers have learned about dietary cholesterol, lipid management and cardiovascular disease risk since the Harvard Egg Study

C. Constance, 2009, International journal of clinical practice. Supplement.

Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).

N. Wenger, C. Jones-Burton, F. Zieve, 2010, The American journal of cardiology.

Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus *

N. Chung, A. Johnson‐Levonas, C. Allen, 2007, Diabetes, obesity & metabolism.

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

G. Breithardt, H. Crijns, P. Mclaughlin, 2016, Journal of the American Heart Association.

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years

N. Wenger, R. Lowe, F. Zieve, 2014, Lipids in Health and Disease.

Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.

B. Egan, K. Andersen, M. Weinberger, 2010, Cardiovascular therapeutics.

Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.

T. S. Chee, D. S. Kim, S. H. Lee, 2022, European journal of preventive cardiology.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, Lancet.